Newlywed, mom ‘COVID long haulers’ battle debilitating symptoms months later

Doctors say they’re bracing for a “tsunami” of “COVID long haulers”

As the coronavirus pandemic continues across the U.S., experts are noticing another wave of the pandemic with what they’re calling “COVID long-haulers,” or people suffering debilitating symptoms months after having the coronavirus.

Doctors say they are seeing many people who have recovered from COVID but are finding themselves still not well.

Caitlin Barber, a 27-year-old newlywed, is one of these “COVID long haulers,” who led a healthy lifestyle with her husband and spent time training as a runner. She was also a dietician at a nursing home.

Caitlin Barber poses for a photo after a marathon.

Caitlin Barber poses for a photo after a marathon.

Caitlin Barber poses for a photo after a marathon.

“We were living the newlywed dream, you know and loving life,” Barber told “Good Morning America.”

Read More

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms

Charles Lapp, MD

Charles Lapp, MD, at a recent AIM ImmunoTech Inc. planning meeting on COVID-19-induced chronic fatigue in ‘Long Haulers,’ at the Hunter-Hopkins Center, Charlotte, N.C.
Charles Lapp, MD, at a recent AIM ImmunoTech Inc. planning meeting on COVID-19-induced chronic fatigue in ‘Long Haulers,’ at the Hunter-Hopkins Center, Charlotte, N.C.
Charles Lapp, MD, at a recent AIM ImmunoTech Inc. planning meeting on COVID-19-induced chronic fatigue in ‘Long Haulers,’ at the Hunter-Hopkins Center, Charlotte, N.C.

OCALA, Fla., Oct. 06, 2020 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) is pleased to announce that it has received Institutional Review Board (IRB) approval for the expansion of the AMP-511 Expanded Access Program (EAP) clinical trial for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) to include patients previously diagnosed with SARS-CoV-2, but who still demonstrate chronic fatigue-like symptoms. Patients in the trial are treated with AIM’s flagship pipeline drug Ampligen.

These patients — commonly referred to as Post-COVID-19 Chronic Fatigue (PCCF) / “Long Haulers” because of the persistence of

Read More